Show Notes
Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show up in a clinical setting in the near future? Join host Ken Herrmann, MD with guests Brenda Sandmaier, M...
More from JNM Podcast
Nuclear medicine’s greatest promise is improving patient’s lives, both in quality and longevity, and no one knows that more than patients who have had first-hand experience with nuclear medicine. In fact, it’s often the patients themselves that are our field's greatest advocates. From becoming ambassadors for nuclear medicine to championing FDA approvals of new radiopharmaceuticals to lobbying lawmakers for change, our patients are our most powerful asset. On this episode of the JNM Podcast, ...
Today the JNM Podcast is tackling an in-depth and technical topic: FDA approval pathways for new versions of current radiopharmaceuticals. Often called equivalents, the hope is that these “new” drugs can be expedited to the market by taking the same approval pathway of older, but similar versions. Joining host Ken Herrmann to help navigate these regulatory frameworks are two experts: Tom Hope, MD, and Aman Chauhan, MD. Tune in wherever you stream podcasts! The NCI Cancer Therapy Evaluat...
When it comes to your health, it helps to have the full picture. That’s why total-body PET is such a critical development in medical science: in just one scan, total-body PET can capture every organ and its function from head to toe. This modality is especially helpful for patients with diseases like melanoma or rheumatoid arthritis, as well as various immunology studies that involve analyzing bone marrow. In this episode of the JNM Podcast, host Ken Herrmann is joined by Simon Cherry, Michae...
Live from the 2026 SNMMI Annual Meeting in Los Angeles, California, with Johannes Czernin, MD, and Phillip J. Koo, MD.
Live from the 2026 SNMMI Annual Meeting in Los Angeles, California.